TerminatedPhase 1NCT04879017
FHD-286 in Subjects With Metastatic Uveal Melanoma
Studying Uveal melanoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Foghorn Therapeutics Inc.
- Principal Investigator
- Sarah Reilly, MDFoghorn Therapeutics
- Intervention
- FHD-286(drug)
- Enrollment
- 76 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2023
Study locations (11)
- The Angeles Clinic and Research Institute, Los Angeles, California, United States
- University of Miami Health System, Sylvester Comprehensive Cancer Center, Miami, Florida, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Dana Farber Cancer Institute, Boston, Massachusetts, United States
- Columbia University, Herbert Irving Comprehensive Cancer Center, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- Sidney Kimmel Cancer Center - Jefferson Health, Philadelphia, Pennsylvania, United States
- Sarah Cannon Research Institute, Nashville, Tennessee, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Institute Curie Hospital, Paris, France
- Leiden University Medical Center, Leiden, Netherlands
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04879017 on ClinicalTrials.govOther trials for Uveal melanoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07364474Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the LiverMassachusetts General Hospital
- RECRUITINGPHASE3NCT07015190Neoadjuvant Darovasertib in Primary Uveal MelanomaIDEAYA Biosciences
- RECRUITINGPHASE2NCT07276386Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal MelanomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE1, PHASE2NCT06961357Clinical Trial of CD40L-augmented TIL for Patients With Advanced MelanomaH. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGPHASE1NCT07203391Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell HomeostasisSt Vincent's Hospital, Sydney
- RECRUITINGPHASE1NCT07076550A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic MelanomaAlpha-9 Oncology USA Inc.
- RECRUITINGNCT07421739Choroidal Melanoma Patient-Reported Outcome Study (CM-PRO) in a Subset of AU-011-301 (CoMpass) SubjectsAura Biosciences
- RECRUITINGPHASE1, PHASE2NCT06626516Tebentafusp-tebn With LDT in Metastatic UMThomas Jefferson University